Cargando…

Hypogammaglobulinemia and Infections in Patients With Multiple Sclerosis Treated With Rituximab

BACKGROUND AND OBJECTIVES: To determine the frequency of hypogammaglobulinemia and infections in patients with multiple sclerosis (PwMS) receiving rituximab (RTX). METHODS: This prospective observational study included all consecutive PwMS receiving RTX at the university hospital of Marseille, Franc...

Descripción completa

Detalles Bibliográficos
Autores principales:	Perriguey, Marine, Maarouf, Adil, Stellmann, Jan-Patrick, Rico, Audrey, Boutiere, Clemence, Demortiere, Sarah, Durozard, Pierre, Pelletier, Jean, Audoin, Bertrand
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Lippincott Williams & Wilkins 2021
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8611503/ https://www.ncbi.nlm.nih.gov/pubmed/34815322 http://dx.doi.org/10.1212/NXI.0000000000001115

Ejemplares similares

Efficacy of Rituximab Outlasts B-Cell Repopulation in Multiple Sclerosis: Time to Rethink Dosing?
por: Claverie, Roxane, et al.
Publicado: (2023)

Rituximab-Induced Hypogammaglobulinemia and Infections in AQP4 and MOG Antibody–Associated Diseases
por: Avouac, Alexandre, et al.
Publicado: (2021)

Extending rituximab dosing intervals in patients with MS during the COVID-19 pandemic and beyond?
por: Maarouf, Adil, et al.
Publicado: (2020)

Disease Evolution in Women With Highly Active MS Who Suspended Natalizumab During Pregnancy vs Rituximab/Ocrelizumab Before Conception
por: Demortiere, Sarah, et al.
Publicado: (2023)

Determining the best window for BNT162b2 mRNA vaccination for SARS-CoV-2 in patients with multiple sclerosis receiving anti-CD20 therapy
por: Rico, Audrey, et al.
Publicado: (2021)

Pure Relapsing Short Myelitis: Part of the Multiple Sclerosis Spectrum or New Entity?
por: Poullet, Zélia, et al.
Publicado: (2022)

Cognitive performance shows domain specific associations with regional cortical thickness in multiple sclerosis
por: Stellmann, Jan-Patrick, et al.
Publicado: (2021)

Rituximab Use and Hypogammaglobulinemia
por: Alhassan, Eaman, et al.
Publicado: (2020)

High levels of serum soluble TWEAK are associated with neuroinflammation during multiple sclerosis
por: Maarouf, Adil, et al.
Publicado: (2019)

TNF-α inhibitors used as steroid-sparing maintenance monotherapy in parenchymal CNS sarcoidosis
por: Hilezian, Frédéric, et al.
Publicado: (2021)

Rituximab Associated Hypogammaglobulinemia in Autoimmune Disease
por: Tieu, Joanna, et al.
Publicado: (2021)

Hypogammaglobulinemia, infections and COVID-19 in people with multiple sclerosis treated with ocrelizumab
por: Habek, Mario, et al.
Publicado: (2022)

Rituximab-associated Hypogammaglobulinemia in pediatric patients with autoimmune diseases
por: Khojah, Amer M., et al.
Publicado: (2019)

Association of Immunoglobulin Levels, Infectious Risk, and Mortality With Rituximab and Hypogammaglobulinemia
por: Barmettler, Sara, et al.
Publicado: (2018)

Rituximab-induced hypogammaglobulinemia in patients with neuromyelitis optica spectrum disorders
por: Marcinnò, Andrea, et al.
Publicado: (2018)

Is Rituximab-Associated Hypogammaglobulinemia Always Linked to B-Cell Depletion?
por: Damianaki, Anthie, et al.
Publicado: (2022)

Aerobic Exercise Induces Functional and Structural Reorganization of CNS Networks in Multiple Sclerosis: A Randomized Controlled Trial
por: Stellmann, Jan-Patrick, et al.
Publicado: (2020)

Secondary Hypogammaglobulinemia After Rituximab for Neuromyelitis Optica: A Case Report
por: Farhat, Lara, et al.
Publicado: (2018)

Hypogammaglobulinemia following COVID-19 infection in a patient on maintenance rituximab
por: O’Bryan, Collin, et al.
Publicado: (2021)

Rituximab-associated hypogammaglobulinemia in ANCA-associated vasculitis: Incidence and time course
por: Tariq, Anam, et al.
Publicado: (2022)

PD42 - Is rituximab a trigger for persistent hypogammaglobulinemia in idiopathic nephrotic syndrome?
por: Trujillo, Juan Enrique, et al.
Publicado: (2014)

Hypogammaglobulinemia Observed One Year after Rituximab Treatment for Idiopathic Thrombocytopenic Purpura
por: Shoukat, Bilal Ahmad, et al.
Publicado: (2018)

Rituximab-associated hypogammaglobulinemia in children with idiopathic nephrotic syndrome: results of an ESPN survey
por: Zurowska, Aleksandra, et al.
Publicado: (2023)

Prevalence of Grey Matter Pathology in Early Multiple Sclerosis Assessed by Magnetization Transfer Ratio Imaging
por: Crespy, Lydie, et al.
Publicado: (2011)

Delayed access to conscious processing in multiple sclerosis: Reduced cortical activation and impaired structural connectivity
por: Has Silemek, Arzu C., et al.
Publicado: (2021)

New brain lesions with no impact on physical disability can impact cognition in early multiple sclerosis: A ten-year longitudinal study
por: Wybrecht, D., et al.
Publicado: (2017)

Infection Risk, Mortality, and Hypogammaglobulinemia Prevalence and Associated Factors in Adults Treated with Rituximab: A Tertiary Care Center Experience
por: Alhamadh, Moustafa S., et al.
Publicado: (2023)

Low immunoglobulin levels increase the risk of severe hypogammaglobulinemia in granulomatosis with polyangiitis patients receiving rituximab
por: Besada, Emilio
Publicado: (2016)

Rituximab-associated hypogammaglobulinemia in autoimmune rheumatic diseases: a single-center retrospective cohort study
por: Wade, Stefanie D., et al.
Publicado: (2021)

Case report: Persistent hypogammaglobulinemia in thymoma-associated myasthenia gravis: the impact of rituximab or Good's syndrome?
por: Ren, Jingru, et al.
Publicado: (2023)

Persistent Hypogammaglobulinemia after Receiving Rituximab Post-HSCT Is Not Caused by an Intrinsic B Cell Defect
por: Ott de Bruin, Lisa M., et al.
Publicado: (2023)

COVID-19 outcomes in persons with multiple sclerosis treated with rituximab
por: Iyer, Rajesh B, et al.
Publicado: (2022)

Risk Factors and Adverse Events Poorly Predict Infections and Hypogammaglobulinemia in Granulomatosis with Polyangiitis Patients Receiving Rituximab
por: Besada, Emilio
Publicado: (2016)

Fatal Hypogammaglobulinemia 3 Years after Rituximab in a Patient with Immune Thrombocytopenia: An Underlying Genetic Predisposition?
por: Viallard, Jean-François, et al.
Publicado: (2019)

Case Report: Persistent Hypogammaglobulinemia More Than 10 Years After Rituximab Given Post-HSCT
por: Luterbacher, Fanny, et al.
Publicado: (2021)

Characterization of infections and hypogammaglobulinemia treated with the combination of pertuzumab and trastuzumab
por: Mortimer, Joanne E., et al.
Publicado: (2019)

Inflammatory Multiple-Sclerosis Plaques Generate Characteristic Metabolic Profiles in Cerebrospinal Fluid
por: Lutz, Norbert W., et al.
Publicado: (2007)

Hypogammaglobulinemia with Facial Edema
por: Knight, Adina Kay, et al.
Publicado: (2006)

Serious safety events in rituximab‐treated multiple sclerosis and related disorders
por: Vollmer, Brandi L., et al.
Publicado: (2020)

Prolonged COVID-19 in a Multiple Sclerosis Patient Treated With Rituximab
por: Kintrilis, Nikos, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_pt9e7kloh9a58kiq173n6gss7p